Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neuropsychopharmacology is Scopus-indexed (Q1, CiteScore 15.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Nature.
Checked against the index lists dated .
ISSN 0893-133XVerify ISSN ↗1740-634XVerify ISSN ↗
Publisher: Springer Nature
Cost to publish: About US$5,290 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Psychiatry and Mental Health | 12 / 580 | 98th | Q1 |
| Pharmacology | 15 / 328 | 95th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1987–present, best quartile Q1, CiteScore 15.7.
Neuropsychopharmacology is Q1 in Psychiatry and Mental Health (rank 12 of 580) and Q1 in Pharmacology (rank 15 of 328), by CiteScore 2025.
Neuropsychopharmacology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 15.7, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.988, quartile Q1, with an H-index of 269.
The publisher lists an article processing charge of about US$5,290 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Neuropsychopharmacology is published by Springer Nature. Its print ISSN is 0893-133X and its online ISSN is 1740-634X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Neuropsychopharmacology has an h-index of 309 and a 2-year mean of 4.81 citations per paper (OpenAlex). Its Scopus CiteScore is 15.7, quartile Q1. On 2-year citations it ranks #42 of 570 Scopus journals in Psychiatry and Mental Health.
Neuropsychopharmacology published 260 papers in 2025; its busiest recent year was 2020 with 344. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from United States (58.8%), China (6.3%) and Canada (5.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 12 retracted papers are recorded (1.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.